Clinical trials
Pancreatic Adenocarcinoma Advanced or Metastatic clinical trials
Below are recruiting pancreatic adenocarcinoma advanced or metastatic clinical trials, each written for real people, not researchers. We’re tracking 3,872 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06745908RecruitingPhase 3
New drug combo for lung cancer after immunotherapy stops working
This trial tests a new drug combination (N-803 and tislelizumab with chemotherapy) for people whose lung cancer stopped responding to standard immunotherapy. The goal is to see if this treatment can help shrink tumors or slow the cancer's growth.
Springdale, ArkansasAges 18–90 - NCT07686835RecruitingPhase 2
High-fiber diet to help immunotherapy work better in advanced melanoma
This trial tests if adding extra dietary fiber before and during immunotherapy can change gut bacteria to make the treatment more effective. It is for people with advanced melanoma who are about to start their first immunotherapy.
Nijmegen, GelderlandAges 18 years+ - NCT07600749RecruitingPhase 1
MK-4884 study for advanced solid tumors
This early-stage study tests a new drug called MK-4884 in patients with advanced cancers that have spread. The trial includes colorectal, kidney, lung, and bile duct cancers, and aims to find the right dose and see if the drug helps shrink tumors.
San Antonio, TexasAges 18 years+ - NCT07606599RecruitingPhase 3
New drug BL-M07D1 for advanced biliary tract cancer
This trial tests a new drug called BL-M07D1 against standard chemotherapy for biliary tract cancer that has spread or is locally advanced and has stopped responding to platinum-based chemotherapy. The trial is looking for patients whose cancer has a specific genetic marker to see if this new treatment works better.
Hefei, AnhuiAges 18–75 - NCT07582315RecruitingPhase 3
BL-B01D1 for advanced biliary tract cancer after prior treatments
This study tests a new drug called BL-B01D1 against standard treatment options for patients with advanced biliary tract cancer (cancer of the bile ducts) that has stopped responding to platinum chemotherapy and immunotherapy. The drug is designed to target and destroy cancer cells more effectively.
Beijing, Beijing MunicipalityAges 18–75 - NCT06471205RecruitingPhase 2
Study of BL-B01D1 plus immunotherapy for advanced triple-negative breast cancer
This study tests a new drug combination (BL-B01D1 plus an immunotherapy) for people with advanced triple-negative breast cancer who have not had prior treatment for their advanced disease. The goal is to see if the combination works better at shrinking or controlling the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07648914RecruitingPhase 3
BL-B01D1 versus chemotherapy for advanced hormone-receptor-positive breast cancer
This trial tests a new targeted drug called BL-B01D1 against standard chemotherapy in patients with advanced breast cancer that is hormone-receptor-positive (HR+) and HER2-negative, and has stopped responding to hormone treatments. The goal is to see if the new drug works better or has fewer side effects.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06405425RecruitingPhase 2
Study of BL-B01D1 and immunotherapy for advanced bladder cancer
This trial tests a new experimental drug combination (BL-B01D1 with a PD-1 immunotherapy) for advanced bladder cancer that has not yet been treated with whole-body therapy. The goal is to see if this combination can shrink tumors and help people live longer without their cancer getting worse.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06114511RecruitingPhase 1/Phase 2
Study of BL-M07D1 for HER2-mutated advanced lung cancer
This trial tests a new drug, BL-M07D1, for people with a specific type of advanced non-small-cell lung cancer that has a HER2 mutation. The drug targets cancer cells with this mutation, and the study aims to see if it is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT06475300RecruitingPhase 2
BL-B01D1 plus immunotherapy for advanced lung and throat cancers
This trial tests a new combination treatment (BL-B01D1 plus a PD-1 inhibitor) for people with advanced lung cancer or nasopharyngeal cancer. It aims to see if the combination is safe and effective for patients whose cancer has not responded to earlier treatments.
Guangzhou, GuangdongAges 18 years+ - NCT07718490RecruitingPhase 2
Immunotherapy with simvastatin and chemo for advanced colorectal cancer
This trial tests a new combination of immunotherapy, simvastatin (a cholesterol drug), and standard chemotherapy for advanced colorectal cancer that has not been treated before. The goal is to see if adding simvastatin can help the immune system fight the cancer better.
Nanjing, JiangsuAges 18–75 - NCT07124000Recruiting
T-DXd for advanced HER2-positive solid tumors
This trial is for people with advanced HER2-positive solid tumors (cancers that cannot be removed by surgery or have spread). It tests the drug T-DXd (also called Enhertu) when your doctor has already decided it's the right treatment for you and you have no other good options.
Birmingham, AlabamaAges 18–130 - NCT06179160RecruitingPhase 1
Study of INCB161734 for advanced solid tumors with KRAS G12D mutation
This trial tests a new drug called INCB161734 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and helps shrink tumors.
Phoenix, ArizonaAges 18 years+ - NCT05111561RecruitingPhase 1
Testing a two-drug combo for RAS-mutant or triple negative breast cancer
This study tests a combination of two new drugs, ZEN003694 and binimetinib, for people with advanced solid tumors that have certain gene changes (like RAS mutations) or triple negative breast cancer. The goal is to see if this combination can shrink tumors or slow their growth.
Boston, MassachusettsAges 18 years+ - NCT07415564Recruiting
Support program for advanced cancer patients and their caregivers
This trial offers coaching and symptom management support for people with advanced breast, GI, or melanoma cancer and their caregivers. The goal is to improve quality of life for both.
Tucson, ArizonaAges 18 years+ - NCT07030712RecruitingPhase 1
Study of MK-8294 for advanced solid tumors
This trial tests an experimental drug called MK-8294 for people with advanced solid tumors that have stopped responding to standard treatments. It may be an option if you have certain types of cancer and are looking for a new treatment.
Chicago, IllinoisAges 18 years+ - NCT07708194RecruitingPhase 1/Phase 2
Entinostat plus pyrotinib and hormone therapy for advanced breast cancer
This trial tests a new combination of two targeted drugs (entinostat and pyrotinib) with hormone therapy for people with advanced, triple-positive breast cancer whose disease has progressed after trastuzumab (Herceptin). The goal is to see if this approach works better than current options.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06555068RecruitingPhase 1/Phase 2
Study of HRS-6209 combinations for advanced breast cancer
This trial tests a new drug, HRS-6209, combined with different hormone treatments (fulvestrant, letrozole, HRS-8080, or HRS-1358) for people with advanced breast cancer that has spread or cannot be surgically removed and has worsened after previous treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07554456RecruitingPhase 2/Phase 3
New Drug Combination for Advanced Esophageal Cancer
This trial tests a new drug called BL-B01D1 combined with an immune therapy (tislelizumab) and sometimes chemotherapy against standard chemotherapy for esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if this new combination works better and is safer than current treatment.
Beijing, Beijing MunicipalityAges 18–75 - NCT07149649RecruitingPhase 2/Phase 3
Magnesium for advanced lung cancer
This trial tests if adding magnesium supplements to standard first-line treatment (chemotherapy plus immunotherapy) improves outcomes for people with advanced non-small cell lung cancer (NSCLC) that has spread or cannot be removed by surgery. It is for patients who have not had prior treatment for metastatic disease.
AarauAges 18 years+ - NCT07028489Recruiting
Studying a standard-care comparison group for advanced EGFR-mutant lung cancer
This trial collects information from people with a specific type of advanced lung cancer to create a comparison group. It helps researchers understand how well new treatments work without giving any experimental medicine.
Monterey, CaliforniaAges 18 years+ - NCT06937177RecruitingPhase 2
Testing mifomelatide to help maintain weight during chemo
This trial tests an investigational drug called mifomelatide (TCMCB07) to see if it can help people with newly diagnosed colorectal or pancreatic cancer maintain a healthy weight while receiving certain types of chemotherapy. You would give yourself a daily injection under the skin.
Tucson, ArizonaAges 18 years+ - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
Birmingham, AlabamaAges Any age - NCT03521830RecruitingPhase 2
Nivolumab and other immunotherapy for advanced basal cell skin cancer
This study tests how well the immunotherapy medicine nivolumab works—either by itself or combined with other immune-boosting drugs—for people with advanced basal cell carcinoma that can’t be removed by surgery or has spread. It’s also looking at what to do if the cancer grows again after an earlier immunotherapy.
Baltimore, MarylandAges 18 years+
Hear when a new Pancreatic Adenocarcinoma Advanced or Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pancreatic adenocarcinoma advanced or metastatic?
- Yes. Clin2 currently lists 3,872 recruiting pancreatic adenocarcinoma advanced or metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pancreatic adenocarcinoma advanced or metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pancreatic adenocarcinoma advanced or metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Pancreatic Adenocarcinoma
- Locally Advanced Pancreatic Adenocarcinoma
- Metastatic Pancreatic Ductal Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (PDAC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.